Trial reportClinical immunology (Orlando, Fla.)2020
Transcriptional changes in peanut-specific CD4+ T cells over the course of oral immunotherapy.
Trial report in Clinical immunology (Orlando, Fla.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02103270 (Single Center, Placebo Controlled Clinical Study in Desensitization vs Tolerance Induction in Peanut Allergy Subjects), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Single Center, Placebo Controlled Clinical Study in Desensitization vs Tolerance Induction in Peanut Allergy Subjects
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Peanut allergy oral immunotherapy drives single-cell multi-omic changes in peanut-reactive T cells associated with sustained unresponsiveness.Nature immunology · 2025Trial
- Peanut oral immunotherapy differentially suppresses clonally distinct subsets of T helper cells.The Journal of clinical investigation · 2022Trial
- Interleukin-4-producing type 2 innate lymphoid cells in the lymph node promote proallergic Tfh13 cell differentiation.Immunity · 2026Article
- DOCK8 and STAT3 cooperate to restrain IgE-inducing T follicular helper cells.The Journal of experimental medicine · 2026Article
- Modulating the Allergen-Specific Immune Response to Achieve Remission of Food Allergy Through Oral Immunotherapy.Advances in experimental medicine and biology · 2026Review
- Microbiota-derived butyrate alleviates asthma via inhibiting Tfh13-mediated IgE production.Signal transduction and targeted therapy · 2025Article
- New insights into the mechanisms of childhood food allergies.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Review
- Follicular helper T cells (Tfh): heterogeneity in spatial distribution and phenotypic characteristics.Frontiers in immunology · 2025Review
- Contribution of T cell subsets to different food allergic diseases.Immunological reviews · 2024Review
- Triggers for eosinophilic esophagitis (EoE): The intersection of food allergy and EoE.The Journal of allergy and clinical immunology · 2024Review
- Oral immunotherapy with enteric-coated capsules for allergic rhinitis caused by house dust mites.Frontiers in allergy · 2024Article
- Multi-omics profiling approach in food allergy.The World Allergy Organization journal · 2023Review
- Immunotherapy-induced neutralizing antibodies disrupt allergen binding and sustain allergen tolerance in peanut allergy.The Journal of clinical investigation · 2023Article
- T-cell epitope discovery and single-cell technologies to advance food allergy research.The Journal of allergy and clinical immunology · 2023Review
- Advances and potential of omics studies for understanding the development of food allergy.Frontiers in allergy · 2023Review
- Article
- Biomarkers and mechanisms of tolerance induction in food allergic patients drive new therapeutic approaches.Frontiers in immunology · 2022Review
- Identification of antigen-specific TCR sequences based on biological and statistical enrichment in unselected individuals.JCI insight · 2021Article
- Follicular Helper T Cells in the Immunopathogenesis of SARS-CoV-2 Infection.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Oral immunotherapy (OIT) can successfully desensitize allergic individuals to offending foods such as peanut. Our recent clinical trial (NCT02103270) of peanut OIT allowed us to monitor peanut-specific CD4+ T cells, using MHC-peptide Dextramers, over the course of OIT. We used a single-cell targeted RNAseq assay to analyze these cells at 0, 12, 24, 52, and 104 weeks of OIT. We found a transient increase in TGFβ-producing cells at 52 weeks in those with successful desensitization, which lasted until 117 weeks. We also performed clustering and identified 5 major clusters of Dextramer+ cells, which we tracked over time. One of these clusters appeared to be anergic, while another was consistent with recently described TFH13 cells. The other 3 clusters appeared to be Th2 cells by their coordinated production of IL-4 and IL-13, but they varied in their expression of STAT signaling proteins and other markers. A cluster with high expression of STAT family members also showed a possible transient increase at week 24 in those with successful desensitization. Single cell TCRαβ repertoire sequences were too diverse to track clones over time. Together with increased TGFβ production, these changes may be mechanistic predictors of successful OIT that should be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.